[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 18, 2007

Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic ShockLooking for the Reasons

Author Affiliations
 

Author Affiliations: Deutsches Herzzentrum, Technische Universität, Munich, Germany.

JAMA. 2007;297(15):1711-1713. doi:10.1001/jama.297.15.1711

Cardiogenic shock complicating acute myocardial infarction (AMI) is one of the most serious and challenging conditions in cardiovascular medicine, with up to two thirds of patients dying within a few weeks.1,2 According to data from a national registry of nearly 300 000 patients with ST-segment elevation AMI, the overall incidence of cardiogenic shock (diagnosed at both presentation and after admission) was 8.6%.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×